Vaping Expected to Increase COPD Health and Economic Burden by 2050
September 10, 2024 08:00 ET
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024
Wellinks Recognized as Quarterfinalist for the Digital Health Hub Foundation: Digital Health Awards
September 04, 2024 11:00 ET
|
Wellinks Inc.
NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Wellinks, is thrilled to announce its selection as a quarterfinalist for the prestigious 2024 Digital Health Hub Foundation: Digital Health...
Innovative New COPD Maintenance Treatment Now Available Through DirectRx Specialty Pharmacy
August 28, 2024 11:51 ET
|
DirectRx Pharmacy
DirectRx selected for exclusive distribution network for the newest and first-in-class COPD medication, Ohtuvayre by Verona Pharma
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
Wellinks Integrates Virtual Pulmonary Rehabilitation Program at UMass Memorial Health for Massachusetts Residents Living with COPD
August 08, 2024 11:17 ET
|
Wellinks Inc.
NEW HAVEN, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Wellinks, a digital healthcare company offering comprehensive value-based solutions for Chronic Obstructive Pulmonary Disease (COPD) management,...
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
July 18, 2024 06:27 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...